查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1390428

2023-2028年按類型、藥物類別（緩解疾病抗風濕藥、非類固醇類抗發炎藥、皮質類固醇、尿酸藥物等）、藥物管理、配銷通路和地區的抗風濕藥市場報告

Anti-Rheumatics Market Report by Type, Drug Class (Disease Modifying Anti-Rheumatics Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others), Drug Administration, Distribution Channel, and Region 2023-2028
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

概要

2022年全球抗風濕藥市場規模達628億美元。展望未來， IMARC Group預計到2028年市場規模將達到739億美元，2022-2028年複合年成長率（CAGR）為2.75%。全球人口老化加劇，醫院、診所和其他醫療機構的擴張，以及大型製藥公司和醫療中心之間不斷擴大的合作夥伴關係是推動市場成長的一些主要因素。

抗風濕藥是用來治療影響關節、肌肉和結締組織的疾病的藥物。它們有助於減輕發炎、疼痛和僵硬，並減緩疾病的進展。它們有多種類別，包括非類固醇抗發炎藥 (NSAID)、緩解疾病抗風濕藥 (DMARD) 和生物製劑。它們可以透過口服、皮下和靜脈注射進入體內。它們針對導致組織損傷和發炎的潛在機制。它們通常在徹底診斷後開出處方，並結合使用以獲得最佳效果。

由於不健康的飲食模式和缺乏體力活動導致風濕病患病率不斷上升，這是促進有效治療需求的關鍵因素之一。此外，藥物傳輸系統（例如基於奈米顆粒的載體或緩釋膠囊）的持續發展正在增強抗風濕藥物的功效和便利性。除此之外，遠距醫療服務的成長使得更好的疾病管理和更容易的處方補充成為可能，從而促進抗風濕藥物的持續使用。此外，醫療保健系統向新興市場的擴張使得服務不足的人群更容易獲得抗風濕藥物。此外，基因組學和個人化醫療的進步使得更有針對性的治療成為可能，並提高了抗風濕藥物的有效性。

抗風濕藥市場趨勢/促進因素：

人口老化加劇

人口老化加劇，更容易患骨關節炎和類風濕性關節炎等關節疾病，這是促進市場成長的關鍵因素之一。此外，老年族群往往有多種健康狀況，可能會加劇風濕性疾病，因此需要更複雜和長期的治療策略。此外，各國的管理當局和醫療保健系統正在認知到這一日益成長的需求，並正在增加醫療保健預算，以應對老齡化社會的挑戰。製藥公司也將研發工作重點放在創造更有效、更安全的抗風濕藥物。因此，這些藥物的市場預計在未來幾年將大幅成長。

策略合作與合併

製藥公司和醫療保健機構之間的策略合作、併購（M&A）數量不斷增加是推動市場成長的另一個主要因素。它們通常包括知識共享協議，從而更容易克服監管障礙並縮短新藥物的上市時間。此外，大型製藥公司和生技新創公司之間不斷擴大的合作夥伴關係導致新型抗風濕藥物的開發和商業化更快。除此之外，它還促進研發（R&D）活動，以推出更先進的藥物。此外，這些合作促進了抗風濕藥物的輕鬆供應，以進入以前未開發的市場，從而促進全球市場的成長。

提高早期診斷和預防意識

人們對早期診斷和預防類風濕病的好處的認知不斷提高，這正在加強市場的成長。早期診斷可以更有效地治療該疾病，通常需要使用抗風濕藥物。此外，人們越來越依賴社群媒體管道來促進醫學教育，這對市場產生了積極影響。此外，一些國家的管理當局正在組織公共衛生運動，這提供了良好的市場前景。此外，先進診斷工具的發展使醫療保健專業人員更容易在早期發現風濕性疾病。這種積極主動的方法增加了抗風濕藥物的市場需求，因為及時介入需要藥物來控制症狀和改變疾病。

抗風濕藥產業細分：

IMARC Group提供了對市場報告各細分市場主要趨勢的分析，以及 2023 年至 2028 年全球區域和國家層級的預測。我們的報告根據類型、藥物類別、給藥途徑和配銷通路對市場進行了分類。

按類型分類：

處方藥

非處方藥物

處方藥佔大部分市場佔有率

該報告根據類型提供了詳細的市場細分和分析。這包括處方藥和非處方藥。該報告稱，處方藥佔據了最大的佔有率，因為與非處方藥 (OTC) 相比，它們通常更有效、更有針對性。此外，處方藥通常更有可能被保險計劃承保，從而使更多患者群體在經濟上負擔得起。處方藥保險索賠的便利性進一步促進了其使用並有助於擴大其市場佔有率。除此之外，它們還具有定期醫療保健提供者審查的優勢，可以根據疾病的病程和患者的反應不斷調整治療方案。此外，抗風濕治療的最新創新通常是專利處方藥。製藥公司大力投資研發以開發新型處方藥，確保最先進的治療方案主要以處方形式提供。

按藥物類別細分：

疾病緩解抗風濕藥物 (DMARD)

非類固醇類抗發炎藥 (NSAID)

皮質類固醇

降尿酸藥物

其他

疾病緩解抗風濕藥物（DMARD）在業界佔有最大佔有率

報告還提供了基於藥物類別的詳細市場細分和分析。這包括緩解病情抗風濕藥 (DMARD)、非類固醇類抗發炎藥 (NSAID)、皮質類固醇、降尿酸藥物等。根據該報告，疾病緩解抗風濕藥物 (DMARD) 佔了最大的市場佔有率，因為它們在細胞層面發揮作用，調節免疫反應並有助於有效改變風濕病的病程。此外，它們還有助於減少醫院就診、手術和其他昂貴的醫療干預的頻率。除此之外，在許多醫療保健系統中，DMARD 被涵蓋保險範圍計劃中，使更多人在經濟上負擔得起。有效的報銷政策進一步鼓勵DMARD的處方，從而提高其市場佔有率。此外，個人化醫療的不斷進步正在導致更具針對性的DMARD療法的開發，提高其療效並減少潛在的副作用，從而鞏固其市場主導地位。

依給藥途徑細分：

口服

注射用

其他

注射劑代表領先的細分市場

該報告根據給藥途徑對市場進行了詳細的細分和分析。這包括口服、腸胃外和其他。根據該報告，腸胃外給藥是最大的細分市場，因為它可以繞過胃腸道系統，將藥物直接輸送到血液或目標組織。與口服藥物相比，這可以更快起效並且通常提高療效，這是治療風濕病急性發作或嚴重病例的關鍵因素。除此之外，醫生通常更喜歡腸外給藥，因為其作用迅速，特別是在需要立即緩解症狀或控制疾病的醫院環境中。此外，腸外藥物經過嚴格的品質控制措施，以確保無菌和效力，這為醫療保健提供者和患者增加了另一層保證。此外，許多腸胃外製劑均採用預充填注射器或自動注射器，使患者更容易自行給藥，進而提高對治療計畫的遵從性。

按配銷通路分類：

醫院藥房

零售藥局

電子商務

醫院藥局市場主導地位明顯

報告還根據配銷通路對市場進行了詳細的細分和分析。這包括醫院藥房、零售藥房和電子商務。報告稱，醫院藥房佔據了大部分市場佔有率，因為它們通常靠近診間、診斷服務和治療區域。這種集中化允許在診斷或處方修改後立即配發抗風濕藥物，與零售或線上藥局相比，在便利性和速度方面具有優勢。此外，醫院的藥劑師通常接受過治療慢性疾病（包括風濕病）的專門訓練和經驗。他們與包括風濕病專家和護士在內的醫療團隊密切合作，確保患者獲得最適合其病情的藥物。除此之外，他們全天候運作，確保在緊急情況或非工作時間提供藥物。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美市場領先，佔最大的抗風濕藥市場佔有率

市場研究報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美佔據了最大的市場佔有率，因為該地區是藥品研發（R&D）中心。此外，北美，特別是美國，擁有完善的醫療保健系統，配備最先進的醫療設施。這種優越的基礎設施可以實現風濕性疾病的早期診斷和綜合治療，這自然會導致對抗風濕藥物的更高需求。除此之外，專業風濕病診所和醫療專業人員的廣泛使用進一步推動了對這些藥物的需求。除此之外，以美國食品藥物管理局 (FDA) 等機構為主導的北美監管環境非常支持醫療進步。此外，該地區人口老化的加劇正在推動抗風濕藥物的需求。

競爭格局：

公司正大力投資開發新型抗風濕藥物，針對現有和新興的治療機制。此外，許多公司正在建立合作夥伴關係、併購和收購。這些策略合作通常涉及共享技術、資源和市場管道。除此之外，他們也專注於透過各種管道擴大市場准入。這通常涉及在新的地域市場推出產品、提高生產能力或實現供應鏈多元化以確保更可靠的分銷。此外，各種公司正在使用分析來確定市場趨勢、患者偏好和治療結果。此外，他們還投資於醫療保健提供者、患者和公眾的教育計畫。

市場研究報告對競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。市場上的一些主要參與者包括：

艾伯維公司

安進公司

阿斯特捷利康公司

百健公司

百時美施貴寶公司

賽特瑞恩公司

禮來公司

F.霍夫曼-拉羅氏股份公司

強生公司

輝瑞公司

賽諾菲公司

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

最近的發展：

2023 年7 月，艾伯維公司宣布，第3 期Step-Up HS 研究已對第一位患者進行了給藥，該研究旨在評估upadacitinib (RINVOQ (R)) 對患有中度至重度化膿性汗腺炎(HS) 症狀的成人和青少年的療效，但失敗了抗腫瘤壞死因子 (TNF) 療法和一種批准的非抗 TNF 抑制劑療法治療 HS.1

2022 年 11 月，安進公司 (Amgen Inc.) 宣布，將在年度美國風濕病學會會展 (ACR) 上展示其廣泛的既定治療組合和管道資產的臨床和真實資料。

2022 年9 月，Biogen Inc. 宣布歐洲藥品管理局(EMA) 已接受BIIB800 的行銷授權申請(MAA)，BIIB800 是一種生物相似藥候選藥物，參考抗白細胞介素6 受體單株抗體RoACTEMRA ( R)1（托珠單抗） 。

本報告回答的關鍵問題

  • 2022年全球抗風濕藥市場規模是多少
  • 2023-2028年全球抗風濕藥市場的預期成長率是多少
  • 推動全球抗風濕藥物市場的關鍵因素是什麼
  • COVID-19 對全球抗風濕藥市場有何影響
  • 全球抗風濕藥市場按類型分類是怎樣的
  • 根據藥物類別，全球抗風濕藥市場的細分如何
  • 從給藥途徑來看，全球抗風濕藥市場的細分是怎麼樣的
  • 從配銷通路來看，全球抗風濕藥市場的細分如何
  • 全球抗風濕藥市場的重點區域有哪些
  • 10. 全球抗風濕藥市場的主要參與者/公司有哪些？

本報告回答的關鍵問題

  • 2022年全球抗風濕藥市場規模有多大？
  • 2023-2028年全球抗風濕藥市場的預期成長率是多少？
  • 推動全球抗風濕藥市場的關鍵因素是什麼？
  • COVID-19 對全球抗風濕藥市場有何影響？
  • 全球抗風濕藥市場按類型分類是怎樣的？
  • 根據藥物類別，全球抗風濕藥市場的細分如何？
  • 根據給藥途徑，全球抗風濕藥物市場的細分如何？
  • 基於配銷通路的全球抗風濕藥市場的詳細情形如何？
  • 全球抗風濕藥市場的重點區域有哪些？
  • 全球抗風濕藥市場的主要參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球抗風濕藥市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按類型分類的市場細分

  • 處方藥
    • 市場走向
    • 市場預測
  • 非處方藥物
    • 市場走向
    • 市場預測

第 7 章：按藥物類別分類的市場細分

  • 疾病緩解抗風濕藥物 (DMARD)
    • 市場走向
    • 市場預測
  • 非類固醇類抗發炎藥 (NSAID)
    • 市場走向
    • 市場預測
  • 皮質類固醇
    • 市場走向
    • 市場預測
  • 降尿酸藥物
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：依藥品管理途徑分類的市場區隔

  • 口服
    • 市場走向
    • 市場預測
  • 注射用
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：按配銷通路分類的市場區隔

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 電子商務
    • 市場走向
    • 市場預測

第 10 章：按地區分類的市場細分

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Celltrion Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnsons
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112023A4148

Abstract

The global anti-rheumatics market size reached US$ 62.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 73.9 Billion by 2028, exhibiting a growth rate (CAGR) of 2.75% during 2022-2028. The increasing aging population across the globe, expansion of hospitals, clinics, and other healthcare facilities, and the expanding partnerships between large pharmaceutical companies and healthcare centers are some of the major factors propelling the market growth.

Anti-rheumatics are medications used to treat diseases affecting the joints, muscles, and connective tissues. They help reduce inflammation, pain, and stiffness, and slow the progression of the disease. They are available in various classes, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologics. They can be administered orally, subcutaneously and intravenously into the body. They target the underlying mechanisms that lead to tissue damage and inflammation. They are generally prescribed after a thorough diagnosis and are used in combination for optimum results.

The rising prevalence of rheumatic diseases due to unhealthy dietary patterns and lack of physical activity represent one of the key factors catalyzing the demand for effective treatments. Additionally, continuous development in drug delivery systems, like nanoparticle-based carriers or time-release capsules, is enhancing the efficacy and convenience of anti-rheumatic medications. Apart from this, the growth of telehealth services is enabling better disease management and easier prescription refills, promoting consistent use of anti-rheumatic drugs. Furthermore, the expansion of healthcare systems into emerging markets is making anti-rheumatic medications more accessible to underserved populations. Moreover, advancements in genomics and personalized medicine are allowing for more targeted treatments and improving the effectiveness of anti-rheumatic medications.

Anti-Rheumatics Market Trends/Drivers:

Rising aging population

The increasing aging population, which is more susceptible to joint disorders, such as osteoarthritis and rheumatoid arthritis, represents one of the key factors augmenting the market growth. Moreover, older populations often have multiple health conditions that can exacerbate rheumatic diseases, thus requiring more complex and long-term treatment strategies. Additionally, governing authorities and healthcare systems of various countries are recognizing this growing need and are increasing healthcare budgets to address the challenges of an aging society. Pharmaceutical companies are also focusing their research and development efforts on creating more effective and safer anti-rheumatic medications. As a result, the market for these drugs is expected to grow substantially in the coming years.

Strategic collaborations and mergers

The increasing number of strategic collaborations, mergers, and acquisitions (M&A) among pharmaceutical companies and healthcare facilities is another major factor contributing to the market growth. They often include knowledge-sharing agreements, making it easier to navigate regulatory hurdles and reducing the time-to-market for new medications. Additionally, the expanding partnerships between large pharmaceutical companies and biotech startups result in the faster development and commercialization of new anti-rheumatic drugs. Apart from this, it facilitates research and development (R&D) activities to introduce more advanced drugs. Furthermore, these collaborations promote an easy supply of anti-rheumatic drugs to reach previously untapped markets, contributing to global market growth.

Rising awareness about early diagnosis and prevention

The rising awareness among individuals about the benefits of early diagnosis and prevention of rheumatoid diseases is strengthening the growth of the market. Early diagnosis allows for more effective management of the disease, often requiring the use of anti-rheumatic drugs. Additionally, the increasing reliance of people on social media channels promoting medical education is positively influencing the market. Furthermore, the governing authorities of several countries are organizing public health campaigns, which is offering a favorable market outlook. Moreover, the development of advanced diagnostic tools has made it easier for healthcare professionals to identify rheumatic diseases at an early stage. This proactive approach enhances the market demand for anti-rheumatics, as timely intervention necessitates medication for symptom management and disease modification.

Anti-Rheumatics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market report, along with forecasts at the global regional, and country levels from 2023-2028. Our report has categorized the market based on type, drug class, route of drug administration and, distribution channel.

Breakup by Type:

Prescription-based Drugs

Over-the-Counter Drugs

Prescription-based drugs account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes prescription-based drugs and over-the-counter drugs. According to the report, prescription-based drugs represented the largest segment as they are usually more potent and targeted compared to over the counter (OTC) options. Additionally, prescription- based medications are generally more likely to be covered by insurance plans, making them financially accessible for a larger patient population. The ease of insurance claims for prescription drugs further promotes their usage and contributes to their larger market share. Apart from this, they come with the advantage of regular healthcare provider reviews, allowing for ongoing adjustments to the treatment regimen based on the course of the diseases and patient response. Furthermore, the latest innovations in anti-rheumatic treatments are often patented prescription medications. Pharmaceutical companies invest significantly in R&D to develop novel prescription drugs, ensuring that the most advanced treatment options are primarily available in prescription form.

Breakup by Drug Class:

Disease Modifying Anti-Rheumatics Drugs (DMARD's)

Nonsteroidal Anti-Inflammatory Drugs (NSAID's)

Corticosteroids

Uric Acid Drugs

Others

Disease modifying anti-rheumatics drugs (DMARD's) hold the largest share in the industry

A detailed breakup and analysis of the market based on the drug class has also been provided in the report. This includes disease modifying anti-rheumatics drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. According to the report, disease modifying anti-rheumatics drugs (DMARD's) accounted for the largest market share as they work at a cellular level to modulate the immune response and aid in effectively altering the course of rheumatic diseases. Additionally, they help reduce the frequency of hospital visits, surgeries, and other expensive medical interventions. Apart from this, in many healthcare systems, DMARDs are included in insurance coverage plans, making them financially accessible to a larger population. Effective reimbursement policies further encourage the prescription of DMARDs, thus enhancing their market share. Moreover, continuous advancements in personalized medicine are leading to the development of more targeted DMARD therapies, enhancing their efficacy and reducing potential side effects, thereby reinforcing their market dominance.

Breakup by Route of Drug Administration:

Oral

Parenteral

Others

Parenteral represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the route of drug administration. This includes oral, parenteral, and others. According to the report, parenteral represented the largest segment as it allows for the direct delivery of drug into the bloodstream or target tissue, bypassing the gastrointestinal system. This results in a quicker onset of action and often increased efficacy compared to oral medications, which is a crucial factor in treating acute flare-ups or severe cases of rheumatic diseases. Apart from this, physicians often prefer parenteral administration for its rapid action, especially in hospital settings where immediate symptom relief or disease control is required. Moreover, parenteral medications undergo stringent quality control measures to ensure sterility and potency, which adds another layer of assurance for both healthcare providers and patients. Furthermore, many parenteral formulations are available in pre-filled syringes or auto-injectors, making it easier for patients to self-administer their medication, thereby enhancing adherence to treatment plans.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

E-Commerce

Hospital pharmacies exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and e-commerce. According to the report, hospital pharmacies hold the majority of the market share as they are generally situated in close proximity to consultation rooms, diagnostic services, and treatment areas. This centralization allows for the immediate dispensing of anti-rheumatic medications following a diagnosis or prescription revision, providing an advantage in terms of convenience and speed over retail or online pharmacies. Additionally, pharmacists in hospital settings often have specialized training and experience in managing chronic diseases, including rheumatic conditions. They work in close collaboration with healthcare teams, including rheumatologists and nurses, ensuring that patients receive the most appropriate medication for their condition. Apart from this, they operate round-the-clock, ensuring that medications are available during emergencies or off-hours.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest anti-rheumatics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region is a hub for pharmaceutical research and development (R&D). Additionally, North America, particularly the United States, has a well-established healthcare system equipped with state-of-the-art medical facilities. This superior infrastructure allows for the early diagnosis and comprehensive treatment of rheumatic diseases, which naturally leads to a higher demand for anti-rheumatic medications. Along with this, the widespread availability of specialized rheumatology clinics and medical professionals further drives the need for these drugs. Apart from this, the regulatory environment in North America, led by agencies like the U.S. Food and Drug Administration (FDA), is highly supportive of medical advancements. Furthermore, the increasing aging population in the region is driving the demand for anti-rheumatics.

Competitive Landscape:

Companies are investing heavily in the development of new anti-rheumatic drugs, targeting existing and emerging therapeutic mechanisms. Additionally, many companies are entering into partnerships, mergers, and acquisitions. These strategic collaborations often involve sharing technology, resources, and market channels. Apart from this, they are also focusing on expanding market access through various channels. This often involves launching products in new geographical markets, increasing production capacities, or diversifying supply chains to ensure more reliable distribution. Furthermore, various companies are using analytics to identify market trends, patient preferences, and treatment outcomes. Moreover, they are investing in educational programs for healthcare providers, patients, and the public.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amgen Inc.

AstraZeneca plc

Biogen Inc.

Bristol-Myers Squibb Company

Celltrion Inc.

Eli Lilly and Company

F. Hoffmann-La Roche AG

Johnson & Johnsons

Pfizer Inc.

Sanofi SA

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Recent Developments:

In July 2023, AbbVie Inc. announced that the first patient has been dosed in the Phase 3 Step-Up HS study to evaluate upadacitinib (RINVOQ®) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) symptoms and have failed anti-tumor necrosis factor (TNF) therapy and one approved non-anti-TNF inhibitor therapy for HS.1

In November 2022, Amgen Inc. announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR).

In September 2022, Biogen Inc. announced that the European Medicines Agency (EMA) had accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody.

Key Questions Answered in This Report

  • 1. What was the size of the global anti-rheumatics market in 2022?
  • 2. What is the expected growth rate of the global anti-rheumatics market during 2023-2028?
  • 3. What are the key factors driving the global anti-rheumatics market?
  • 4. What has been the impact of COVID-19 on the global anti-rheumatics market?
  • 5. What is the breakup of the global anti-rheumatics market based on the type?
  • 6. What is the breakup of the global anti-rheumatics market based on the drug class?
  • 7. What is the breakup of the global anti-rheumatics market based on the route of drug administration?
  • 8. What is the breakup of the global anti-rheumatics market based on the distribution channel?
  • 9. What are the key regions in the global anti-rheumatics market?
  • 10. Who are the key players/companies in the global anti-rheumatics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Rheumatics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription-based Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-Counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Disease Modifying Anti-Rheumatics Drugs (DMARD's)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Corticosteroids
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Uric Acid Drugs
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Route of Drug Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Parenteral
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 E-Commerce
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Biogen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bristol-Myers Squibb Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Celltrion Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 F. Hoffmann-La Roche AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
    • 15.3.9 Johnson & Johnsons
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi SA
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Anti-Rheumatics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Rheumatics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Anti-Rheumatics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Anti-Rheumatics Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Anti-Rheumatics Market: Breakup by Drug Class (in %), 2022
  • Figure 6: Global: Anti-Rheumatics Market: Breakup by Route of Drug Administration (in %), 2022
  • Figure 7: Global: Anti-Rheumatics Market: Breakup by Distribution Channel (in %), 2022
  • Figure 8: Global: Anti-Rheumatics Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Anti-Rheumatics (Prescription-based Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Anti-Rheumatics (Prescription-based Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Anti-Rheumatics (Over-the-Counter Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Anti-Rheumatics (Over-the-Counter Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Anti-Rheumatics (Disease Modifying Anti-Rheumatics Drugs (DMARD's)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Anti-Rheumatics (Disease Modifying Anti-Rheumatics Drugs (DMARD's)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Anti-Rheumatics (Nonsteroidal Anti-Inflammatory Drugs (NSAID's)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Anti-Rheumatics (Nonsteroidal Anti-Inflammatory Drugs (NSAID's)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Anti-Rheumatics (Corticosteroids) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Anti-Rheumatics (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Anti-Rheumatics (Uric Acid Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Anti-Rheumatics (Uric Acid Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Anti-Rheumatics (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Anti-Rheumatics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Anti-Rheumatics (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Anti-Rheumatics (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Anti-Rheumatics (Parenteral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Anti-Rheumatics (Parenteral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Anti-Rheumatics (Other Routes of Drug Administration) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Anti-Rheumatics (Other Routes of Drug Administration) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Anti-Rheumatics (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Anti-Rheumatics (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Anti-Rheumatics (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Anti-Rheumatics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Anti-Rheumatics (E-Commerce) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Anti-Rheumatics (E-Commerce) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: North America: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: North America: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: United States: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: United States: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Canada: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Canada: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Asia-Pacific: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Asia-Pacific: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: China: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: China: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Japan: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Japan: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: India: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: India: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: South Korea: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: South Korea: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Australia: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Australia: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Indonesia: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Indonesia: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Others: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Europe: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Europe: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Germany: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Germany: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: France: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: France: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: United Kingdom: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: United Kingdom: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Italy: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Italy: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Spain: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Spain: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Russia: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Russia: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Others: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Latin America: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Latin America: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Brazil: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Brazil: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Mexico: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Mexico: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Others: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Middle East and Africa: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Middle East and Africa: Anti-Rheumatics Market: Breakup by Country (in %), 2022
  • Figure 83: Middle East and Africa: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Global: Anti-Rheumatics Industry: SWOT Analysis
  • Figure 85: Global: Anti-Rheumatics Industry: Value Chain Analysis
  • Figure 86: Global: Anti-Rheumatics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Rheumatics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Anti-Rheumatics Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Anti-Rheumatics Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 4: Global: Anti-Rheumatics Market Forecast: Breakup by Route of Drug Administration (in Million US$), 2023-2028
  • Table 5: Global: Anti-Rheumatics Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 6: Global: Anti-Rheumatics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Anti-Rheumatics Market: Competitive Structure
  • Table 8: Global: Anti-Rheumatics Market: Key Players